Pro­to­cols: With Nin­laro sales suf­fer­ing, Take­da launch­es huge mul­ti­ple myelo­ma study; Medi­vir split­ting, spin­ning R&D in­to a sep­a­rate com­pa­ny

Take­da is rolling out a ma­jor new study in­volv­ing mul­ti­ple myelo­ma pa­tients. Re­searchers are re­cruit­ing 5,000 pa­tients to track their re­al world ex­pe­ri­ence in be­ing treat­ed for the dis­ease. Take­da bagged an FDA ap­proval for Nin­laro last fall, but they’ve ex­pe­ri­enced dis­ap­point­ing sales so far. It’s al­so been blocked in Eu­rope.

Swe­den’s Medi­vir is push­ing ahead with plans to di­vide the com­pa­ny in­to two in­de­pen­dent en­ti­ties, split­ting its com­mer­cial op­er­a­tions and R&D port­fo­lio. The move is ex­pect­ed to wrap up by the end of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER